Reducing Cardiovascular Risk With Effective Management Of LDL Cholesterol - A Round Table Discussion

Published: 18 December 2020

  • Views:

    Views Icon 79
  • Likes:

    Heart Icon 7
  • episode_image
    Now Playing
    Part 6
    Chapter 6: Summary
    Kausik (Kosh) Ray, Lale Tokgözoğlu, Christie Ballantyne
    Up Next
Average (ratings)
No ratings
Your rating

Overview

This round table is designed to provide clinicians with a better understanding of the long-term CV risks of LDL-C exposure. In addition to reviewing the pathogenesis of atherosclerosis and assessing the long term implications of elevated LDL-C, this meeting will consider current guidance around controlling LDL-C, the challenges in achieving LDL-C targets, and evaluate how emerging strategies are contributing to LDL-C management.

 

Each chapter will comprise of a short presentation by the named medical expert followed by a panel discussion amongst all faculty.

This medical experts round table discussion was organised independently by Radcliffe Cardiology, work that was funded by Novartis. It is intended for healthcare professionals as medical educational material, and may include data/information on investigational uses of compounds/drugs that have not yet been approved by regulatory authorities.

Learning objectives

  • Outline the pathogenic nature and clinical risk of extended exposure to elevated LDL-C
  • Describe the clinical challenges in achieving guideline-based LDL-C goals
  • Compare and contrast LDL-C lowering therapies

More from this programme

Part 1

Chapter 1: Welcome and introductions

Part 2

Chapter 2: The role of long-term exposure to elevated LDL-C in the pathogenesis of atherosclerosis and clinical risk

Part 3

Chapter 3: Current approaches to controlling LDL-C – what do the guidelines say?

Part 4

Chapter 4: Challenges in achieving guideline-based LDL-C targets in the real world

Part 5

Chapter 5: Contemporary approaches to managing LDL-C and cardiovascular risk

Part 6

Chapter 6: Summary

Faculty Biographies

Kausik (Kosh) Ray

Kausik (Kosh) Ray

Professor of Public Health

Kausik Ray is currently Professor of Public Health, Deputy Director of Imperial Clinical Trials Unit and Head of Commercial Trials within the Department of Public Health and Primary Care, School of Public Health, Imperial College London, Consultant Cardiologist and Chief Clinical Officer and Head of Trials – Discover Now as well as NIHR ARC National Lead of Cardiovascular Disease.

Professor Ray received his medical education (MB ChB, 1991) at the University of Birmingham Medical School, his MD (2004) at the University of Sheffield, a postdoctoral fellowship at Harvard Medical School and finally an MPhil in epidemiology (2007) from the University of Cambridge.
A Fellow of the American College of Cardiology, the European Society of Cardiology, the American Heart Association and the Royal College of Physicians, Kausik Ray is also a member of the British Cardiovascular Society and President-Elect of the European Atherosclerosis Society, also serving on the EAS Consensus…

View full profile
Lale Tokgözoğlu

Lale Tokgözoğlu

Professor Cardiology, Haceteppe University, Ankara, Turkey

S. Lale Tokgözoglu is Professor of Cardiology at Hacettepe University, Ankara, Turkey. She is currently the President of the European Atherosclerosis Society and Deputy Editor of the European Heart Journal. She chaired the ‘Atherosclerosis and Vascular Biology Working Group of the European Society of Cardiology’ between 2008 and 2010. Professor Tokgözoglu has served on the Board of the Turkish Society of Cardiology and was elected to be the first female President of the Society in its history, between 2014-2016. During that time, she worked with the Ministry of Health to develop ‘Heart Health policies’ and strategies. She also chaired the Dyslipidaemia Working Group of the Turkish Society of Cardiology.

Professor Tokgözoglu has contributed to several Guidelines and Consensus Papers on dyslipidaemia and Preventive Cardiology both in Europe and nationally. She was a member of the Steering Committee of the EUROASPIRE studies and has also served on the Board of the Prevention…

View full profile
Christie Ballantyne

Christie Ballantyne

Chief of Cardiology and Chief of Cardiovascular Research at Baylor College of Medicine, Houston, Texas

Christie Ballantyne is an internationally-renowned expert on lipids, atherosclerosis and heart disease prevention. His research interest in the prevention of heart disease has led him to become an established investigator for the American Heart Association and to receive continuous funding from the NIH since joining the faculty in 1988 in basic research of leukocyte- endothelial interactions, translational research in biomarkers and clinical trials.
Over the past 32 years, his many accomplishments have included being elected as Fellow of the American Association for the Advancement of Science, the American Society of Clinical Investigation, and the Association of American Physicians. In 2012 he received the American College of Cardiology Distinguished Scientist Award (Basic Domain). In 2014 and 2015, Thomson Reuters recognized Christie as one of “The World's Most Influential Scientific Minds.” Clarivate Analytics, Web of Science, named Dr. Ballantyne as a “Highly Cited…

View full profile